Marshall Financial Group LLC Sells 1,108 Shares of Medpace Holdings, Inc. $MEDP

Marshall Financial Group LLC decreased its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 35.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,006 shares of the company’s stock after selling 1,108 shares during the quarter. Marshall Financial Group LLC’s holdings in Medpace were worth $1,127,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. True Wealth Design LLC lifted its position in shares of Medpace by 19.5% in the 4th quarter. True Wealth Design LLC now owns 264 shares of the company’s stock worth $148,000 after purchasing an additional 43 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in Medpace by 44.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 21,942 shares of the company’s stock worth $13,437,000 after buying an additional 6,749 shares during the period. NorthCrest Asset Manangement LLC boosted its position in Medpace by 73.8% during the 4th quarter. NorthCrest Asset Manangement LLC now owns 3,470 shares of the company’s stock valued at $2,036,000 after acquiring an additional 1,474 shares in the last quarter. Nordea Investment Management AB grew its holdings in shares of Medpace by 1.9% during the 4th quarter. Nordea Investment Management AB now owns 63,784 shares of the company’s stock worth $35,930,000 after acquiring an additional 1,166 shares during the period. Finally, Occidental Asset Management LLC bought a new position in shares of Medpace in the 4th quarter worth approximately $279,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Zacks Research lowered Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a report on Wednesday, January 28th. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target for the company in a research note on Friday, February 13th. Royal Bank Of Canada began coverage on shares of Medpace in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $522.00 price objective on the stock. Finally, TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and decreased their target price for the company from $462.00 to $419.00 in a research note on Wednesday, February 18th. Five equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $486.67.

Insider Activity

In other news, President Jesse J. Geiger sold 31,707 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president owned 15,000 shares in the company, valued at approximately $6,829,500. This represents a 67.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 20.30% of the company’s stock.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $452.51 on Monday. The business has a fifty day moving average price of $509.09 and a 200-day moving average price of $538.69. The company has a market capitalization of $12.84 billion, a PE ratio of 29.58, a PEG ratio of 2.17 and a beta of 1.44. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The company had revenue of $708.45 million for the quarter, compared to analysts’ expectations of $689.53 million. During the same quarter in the previous year, the business posted $3.67 EPS. Medpace’s revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.